Advances in Endometrial Cancer: From Pathogenesis, Pathology Diagnosis and Molecular Classification to Targeted Therapy
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 16309
Special Issue Editor
Interests: endometrial serous carcinogenesis; endometrial cancer pathogenesis; TCGA-endometrial cancer molecular classification; targeted therapy; immune therapy; uterine sarcoma; clinical trials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Endometrial cancer is the most common gynecologic malignancy and the fourth most common malignancy among women in the United States. The incidence of endometrial cancer continues to rise as the life expectancy of women increases. This Special Issue focuses on recent developments in the pathogenesis, molecular diagnosis and treatment of all histologic types of endometrial cancer.
This Special Issue will cover reports of clinically oriented pathogenesis-associated research findings, the impact of TCGA molecular classification in guidance on prognosis, the pros and cons of adjuvant therapies, preclinical data and clinical trials of targeted as well as immune therapies, and the development of novel treatment strategies. Research in formats including original research, reviews and commentary reviews are welcome. This Special Issue is expected to provide the most updated therapeutic-related advances and possible future directions in endometrial cancer.
Prof. Wenxin Zheng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrial cancer
- endometrial carcinoma
- uterine cancer
- uterine sarcoma
- TCGA molecular classification
- endometrial cancer pathology
- endometrial cancer pathogenesis
- chemotherapy
- radiotherapy
- chemoradiotherapy
- PORTEC studies
- immunotherapy
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
